Welcome to the Jason Carter Clinical Trials Website
Our website helps patients find clinical trials. We currently offer patient-friendly descriptions of leukemia and lymphoma trials. Early in 2018, we will be:
Adding patient-friendly trial descriptions for other blood cancers and disorders
Making improvements to the search tool
Expanding our educational resources
Didn't find a trial or need help? Contact our clinical trial specialist at 888-814-8610 or contact@ctsearchsupport.org.
Two drugs, mosunetuzumab and polatuzumab vedotin, either alone or in combination, to treat diffuse large B-cell lymphoma (DLBCL), grade 3b follicular lymphoma or primary mediastinal large B-cell lymphoma (PMBCL) that has come back (relapsed) or not gotten better with treatment (refractory) after CAR T-cell therapy
To find out if mosunetuzumab and polatuzumab vedotin are safe and work well to treat DLBCL, grade 3b follicular lymphoma or PMBCL that has relapsed or is refractory after CAR T-cell therapy
You may be able to join this trial if you:
Are 18 years or older
Have any of the following that has relapsed or is refractory:
DLBCL
Grade 3b follicular lymphoma
PMBCL
Are able to receive CAR T-cell therapy. Your doctor can tell you this
Do not have lymphoma in your brain or spinal cord
Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CAR stands for chimeric antigen receptors and T stands for T cells, a type of immune cell. This treatment helps your own immune system find and destroy cancer cells. Cyclophosphamide and fludarabine are drugs that block the growth of cancer cells. Mosunetuzumab is a T-cell engaging bispecific antibody that target CD20 and CD3 on certain cells. Polatuzumab vedotin is a monoclonal antibody-drug conjugate, or combination, that targets CD79b on certain cells.
To make CAR T cells, T cells are collected from you by apheresis. Apheresis is a process to collect cells from the bloodstream using a needle similar to when you donate blood. The T cells are genetically modified to grow special proteins called CARs. CARs help T cells find the cancer cells. The CAR T cells are grown in a lab until there are millions of them. Then, they’re given back to you to find and destroy the cancer cells.
Before the CAR T-cell infusion, you’ll get chemotherapy (chemo) with 2 standard drugs:
Cyclophosphamide – Given as intravenous (IV) infusions
Fludarabine – Given as IV infusions
Then, the CAR T cells are given to you through an IV infusion. The dose of cells you’ll get depends on when you start the trial and how safe it has been.
You'll then be randomized to 1 of 3 groups. Once you’re randomized, you’ll be told what group you’re in:
Group 1 – Mosunetuzumab
Group 2 – Polatuzumab vedotin
Group 3 – Mosunetuzumab plus polatuzumab vedotin
Randomized means doctors will use a computer to assign you to a group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You’ll get:
Mosunetuzumab – Group 1 and 3 only - Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
Polatuzumab vedotin – Group 2 only - Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 15 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat DLBCL, grade 3b follicular lymphoma or PMBCL that has relapsed or is refractory after CAR T-cell therapy is new and unproven.
